AEYE-DS
FDA-cleared, fully autonomous AI for diabetic retinopathy screening with portable and desktop cameras
The fastest-growing diabetic retinopathy screening solution in the US
1 minute autonomous AI DR exam, 1 image per eye
On the spot diagnostic report
No physician interpretation needed
CPT 92229 reimbursable, closes HEDIS gaps
Portable
AEYE-DS with Optomed
Aurora AEYE
The first and only FDA-cleared, AI-powered diabetic retinopathy solution for a portable camera
92%-93%
Sensitivity
89%-94%
Specificity
> 99%
Success rate
Stationary
Robotic tabletop camera for superior ease of use
_edited.png)
AEYE-DS with Topcon
93%
Sensitivity
91%
Specificity
> 99%
Success rate
Replacing specialist screening with AI diagnosis
Using AI technology, primary care physicians can screen for diabetic retinopathy on the spot, replacing specialist referrals and closing the diabetic retinopathy care gap.
Our Solution: Point-of-Care Screening
GP visit
On-the-spot diagnosis
Positive
Diabetic retinopathy detected - commence treatment
Negative
Cleared for 12 months
Early Detection Prevents Blindness
Accessible and affordable screening for diabetic retinopathy is vital to help ensure patients with diabetes receive sight-saving treatment.
More than
830M
people in the world live with diabetes
Over
40M
people with in US
live with diabetes
At least
85%
of people over 40 with diabetes will develope diabetic retinopathy
< 50%
Less than
of patients with diabetes in the US adhere to their annual eye exams
Catch Our Latest from AEYE Health
.png)
Testimonials
"The time has finally come for autonomous screening technology to exceed the efficacy of the human expert. The implications are that it can be practical for deployment on the front lines of population health – the primary care offices, where over 99% imageability and single image diagnostic acquisition are tantamount to market success"
Sean Ianchulev
MD, MPH, CEO at Eyenovia. Professor of Ophthalmology at UCSF & Mt. Sinai
